Cytovale Appoints Dave Vort as Chief Commercial Officer

Cytovale, a medical diagnostics company focused on AI-enabled rapid sepsis detection, has appointed Dave Vort as their new Chief Commercial Officer. Vort brings over 25 years of experience in the medical device sector to Cytovale, having successfully commercialized disruptive medical technologies at previous firms such as Magnus Medical and iRhythm Technologies. The appointment aligns with Cytovale's strategic move to capitalize on the growing demand for its FDA-cleared IntelliSep diagnostic tool, which assesses the risk of sepsis using a standard blood draw in about eight minutes. Simultaneously, Cytovale secured $100 million in funding to further expand its market presence. The company's innovative approach addresses the critical healthcare challenge of sepsis, impacting more than a third of in-hospital deaths annually in the U.S. and inflicting sizable economic burdens on the healthcare system. Cytovale's board and leadership express commitment toward enhancing patient care through early detection technologies.